Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pituitary Neoplasms 7Prolactinoma 5Polycystic Ovary Syndrome 3Pituitary ACTH Hypersecretion 3Hyperprolactinemia 2Acromegaly 2Recurrence 1Prostatic Neoplasms 1Prolactin Deficiency, Isolated 1Ovarian Hyperstimulation Syndrome 1Neuroendocrine Tumors 1Neoplasms 1Melanoma 1Dumping Syndrome 1Breast Neoplasms 1Brain Neoplasms 1Adrenocortical Hyperfunction 1Adenoma 1ACTH-Secreting Pituitary Adenoma 1

Interventions

Trastuzumab 594Paclitaxel 561Cyclophosphamide 545Docetaxel 478Capecitabine 387Letrozole 350Fulvestrant 310Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 175Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × Cabergoline × Clear all
NCT01730729 2019-09-17

Cabergoline in Metastatic Breast Cancer

Northwestern University

Phase EARLY_PHASE1 Completed
20 enrolled 11 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡